GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (STU:0L8) » Definitions » 3-Year FCF Growth Rate

Lantheus Holdings (STU:0L8) 3-Year FCF Growth Rate : 271.20% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Lantheus Holdings 3-Year FCF Growth Rate?

Lantheus Holdings's Free Cash Flow per Share for the three months ended in Mar. 2024 was €1.56.

During the past 12 months, Lantheus Holdings's average Free Cash Flow per Share Growth Rate was -21.80% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 271.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 38.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Lantheus Holdings was 271.20% per year. The lowest was -57.80% per year. And the median was 20.45% per year.


Competitive Comparison of Lantheus Holdings's 3-Year FCF Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lantheus Holdings's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Lantheus Holdings's 3-Year FCF Growth Rate falls into.



Lantheus Holdings 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Lantheus Holdings  (STU:0L8) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Lantheus Holdings 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Lantheus Holdings (STU:0L8) Business Description

Traded in Other Exchanges
Address
201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Lantheus Holdings (STU:0L8) Headlines

No Headlines